Your session is about to expire
← Back to Search
Small Molecule
VTX2735 for Periodic Syndrome (Explore Trial)
Phase 2
Waitlist Available
Research Sponsored by Zomagen Biosciences, Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from day 1 to completion of treatment with vtx2735, up to day 28
Awards & highlights
Explore Trial Summary
This trial will test if VTX2735 is safe/effective for treating Cryopyrin-Associated Period Syndrome (CAPS) in 10 patients, over a max of 4 weeks.
Eligible Conditions
- Cryopyrin-Associated Periodic Syndromes
Explore Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from day 1 to completion of treatment with vtx2735, up to day 28
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from day 1 to completion of treatment with vtx2735, up to day 28
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety and Tolerability of VTX2735
Secondary outcome measures
Achievement of 30%, 50%, or 75% improvement in mean KSS from baseline
Maximum severity of any symptom score on DHAF2
Mean change in the mean key symptom score (KSS) derived from the Daily Health Assessment Form, Second Generation (DHAF2) from baseline
+2 moreExplore Trial Design
2Treatment groups
Experimental Treatment
Group I: Cohort 2Experimental Treatment1 Intervention
Group II: Cohort 1Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VTX2735
2023
Completed Phase 2
~10
Find a Location
Who is running the clinical trial?
Zomagen Biosciences, LtdLead Sponsor
Matt Cascino, MDStudy DirectorVentyx Biosciences, Inc
1 Previous Clinical Trials
205 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are not willing to stop taking anti-IL-1 therapy and deal with the symptoms of your disease getting worse.You have had a long-lasting or repeat infections.You have experienced at least one worsening of your condition during the screening period.You have severe symptoms or damage from a specific condition that makes it risky to stop taking a certain type of medication.You have hepatitis B, hepatitis C, HIV, AIDS, or active tuberculosis.You have been diagnosed with a specific subtype of a rare condition and have a mild form of the disease.
Research Study Groups:
This trial has the following groups:- Group 1: Cohort 2
- Group 2: Cohort 1
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger